San Francisco / Rochester / Columbus / Seattle / Cambridge / Houston / Los Angeles / Toronto / Melbourne / /
Company
12Foundation Medicine Inc. / /
Country
Canada / Australia / United Kingdom / /
Facility
Research UK Cambridge Institute / Royal Melbourne Hospital / University of Texas MD Anderson Cancer Center / Ohio State University / University of Glasgow / James Cancer Center / University of Cambridge / Margaret Hospital / /
IndustryTerm
gene products / /
MedicalCondition
tumor BRCA / R Cell survival Cell death HRD=HR deficiency / ovarian cancer / measurable disease / Cancer / Identify High-Grade Ovarian Cancer Patient Tumors / endometrioid ovarian cancer / Adequate tumor / RECIST=Response Evaluation Criteria In Solid Tumors / deficiency / /
MedicalTreatment
chemotherapy / /
Organization
UCLA / 4Princess Margaret Hospital / 5The University / University of Cambridge / Ohio State University / James Cancer Center / Li Ka Shing Centre / 2Cancer Research UK Cambridge Institute / Washington School of Medicine / 8Rocky Mountain Cancer Center / 13The Royal Melbourne Hospital / University of Glasgow / Glasgow / University of Texas / /
Person
Elizabeth Swisher / /
ProvinceOrState
Texas / Ohio / Minnesota / California / Massachusetts / Washington / /
ARIEL2: A phase 2 study to prospectively identify ovarian cancer patients likely to respond to rucaparib Elizabeth Swisher,1 James Brenton,2 Scott Kaufmann,3 Amit Oza,4 Robert L. Coleman,5 David O’Malley,6 Gottfried Ko